Chinese Academy of Medical Sciences
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
- Conditions
- EGFR Mutation-Related TumorsStage III Non-small-cell Lung CancerNon Small Cell Lung Cancer
- Interventions
- Radiation: radiation or chemo-radiationDrug: EGFR-TKI Inhibitor
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 450
- Registration Number
- NCT04304638
Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 100
- Registration Number
- NCT04289974
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma
Phase 2
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Procedure: Intensity modulated radiotherapy (IMRT)Drug: Chemotherapy
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 56
- Registration Number
- NCT04275986
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 264
- Registration Number
- NCT04247984
- Locations
- 🇨🇳
Cancer Hospital & Institute, Chinese Academy of Medical Sciences, Beijing, China
Purified Inactivated Japanese Encephalitis Vaccine
Phase 3
- Conditions
- Japanese Encephalitis Virus Disease
- Interventions
- Biological: Japanese Encephalitis Vaccine produced by IMBCAMSBiological: Japanese Encephalitis Vaccine produced by Liaoning Chenda
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 1050
- Registration Number
- NCT04223037
- Locations
- 🇨🇳
Disease prevention and control center of Inner Mongolia autonomous region, Hohhot, Inner Mongolia Autonomous Region, China
Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 108
- Registration Number
- NCT04194684
Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases
Not Applicable
Completed
- Conditions
- Brain Metastases
- Interventions
- Radiation: tomotherapy
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 82
- Registration Number
- NCT04178330
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Beijing, Beijing, China
Tomotherapy for Leptomeningeal Metastases
Not Applicable
Completed
- Conditions
- Leptomeningeal Metastasis
- Interventions
- Radiation: tomotherapy
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 103
- Registration Number
- NCT04178343
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Beijing, Beijing, China
Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer
- Conditions
- HER2-positive Breast Cancer
- Interventions
- Other: non-interventional
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 3000
- Registration Number
- NCT04158505
- Locations
- 🇨🇳
National Cancer Center, Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Phase 2
- Conditions
- Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT04140318
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath